

Q3 2024: Financial Results & Operational Update

Strong Progress Advancing Varoglutamstat in Kidney Disease

December 10, 2024

| Vivoryon Therapeutics N.V.

Important Notice and Disclaimer

This document has been prepared by Vivoryon Therapeutics N.V. (the "Company" or "We") strictly only for discussion purposes. This document does not constitute or form part of any offer or invitation to sell or issue, any offer or inducement or invitation or commitment to purchase or subscribe for, or any solicitation of any offer to purchase or subscribe for, any securities in the Company or any other entity. By reviewing this document, you represent that you are able to receive this document without contravention of any legal or regulatory restrictions applicable to you and will not use this information in relation to any investment decision.

This document and its contents may not be reproduced, redistributed, published or passed on, directly or indirectly, to any other person or published, in whole or in part, for any purpose. Failure to comply with these restrictions may constitute a violation of applicable securities laws. By accepting and reading this document, you will be deemed to agree not to disclose, reproduce or otherwise distribute any information contained herein.

Certain information contained in this document has been obtained from published and non-published sources prepared by third parties. While such information is believed to be reliable for the purposes used herein, none of the Company or its affiliates, directors, officers, employees, members, partners, shareholders or agents make any representation or warranty with respect to or assume any responsibility for the accuracy of such information, and such information has not been independently verified by the Company.

Certain statements contained in this document constitute forward-looking statements, estimates, predictions, influences and projections which are subject to risks and uncertainties and may reflect various assumptions, which may or may not prove to be correct. These forward-looking statements include information about possible or assumed future results of the Company's business, financial condition, results of operations, liquidity, business strategy, management plans and objectives for future operations. In particular, the words "anticipate," "believe," "could," "expect," "should," "plan," "intend," "estimate" and "potential," or other similar expressions are intended to identify forward-looking statements. Forwardlooking statements appear in a number of places in this presentation and include, but are not limited to, statements regarding our intent, belief or current expectations. Forwardlooking statements are based on our management's beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to of various risk factors and uncertainties including without limitation in relation to: the effectiveness of our main product candidate, and our ability to commercialize it if the regulatory approval is obtained; our ability to explore other potential fields of application of our product candidates and benefits of combination therapies between our product candidates and other products; our ability to compete and conduct our business in the future; our ability to expend our limited resources and to obtain funding for our operations necessary to continue as a going concern or to complete further development and commercialization of our product candidates; the timing of and our ability to obtain and maintain regulatory approval for our product candidates; the initiation, timing, progress, results, and cost of our research and development programs and our current and future preclinical studies and clinical trials, including statements regarding the timing of initiation and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available and our research and development programs. These risks and uncertainties and other factors could materially adversely affect the outcome and financial effects of the plans and events described herein. Our results of operations, cash needs, financial condition, liquidity, prospects, future transactions, strategies or events may differ materially from those expressed or implied in such forward-looking statements and from expectations. Moreover, we operate in an evolving environment. Thus, new risk factors and uncertainties emerge from time to time and it is not possible for our management to predict all risk factors and uncertainties, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. We gualify all of our forward-looking statements by these cautionary statements.

Forward-looking statements speak only as of the date they are made, and we do not undertake any obligation to update them in light of new information or future developments or to release publicly any revisions to these statements in order to reflect later events or circumstances or to reflect the occurrence of unanticipated events or otherwise, except as required by applicable law.

Q3 2024 Key Highlights and Post-period Updates



Reported that VIVA-MIND shows highly significant improvement of eGFR versus placebo, confirming VIVIAD eGFR results



Presented kidney outcome results from VIVIAD study in late breaking oral session at ASN Kidney Week, the world's premiere nephrology meeting



Hosted virtual kidney disease KOL event on standard of care and new developments in kidney disease highlighting potential of varoglutamstat




Continued progress in implementing strategic focus on DKD, driven by compelling kidney function data




VAROGLUTAMSTAT MOA & CLINICAL DATA

Groundbreaking discovery: Inhibition of QPCTL reduces kidney inflammation and fibrosis, and improves kidney function



Pyroglutamate formation (pE-formation) is exclusively catalyzed by QPCTL (iso-glutaminyl cyclase enzyme)



© Vivorvon Therapeutics N.V.

pE-CCLx – other potential pE chemokines; Notes: Graphic is for illustrative purposes only.

VIVA-MIND U.S. study design in early AD

1:1 randomization 109 patients treated for up to 72 weeks	Q3 2023 : DSMB cc on 600m	onfirmed continuation	Q2 2024: Decision to discontinue study early ¹		
Placebo					
Varoglutamstat 600mg BID					
 Patients²: Early Alzheimer's disease³ MMSE 20 -30 CDR-SB global score 0.5 or 1 50 – 89 years of age 	 Objectives: Assess the safety and tolerability of value Assess the efficacy of varoglutamstate primary endpoint of CDR-SB Assess the efficacy and pharmacodyn of varoglutamstat at an interim stage of after 180 patients were treated for at 1 	aroglutamstat • e with the p namic effects gate analysis	ney Function: GFR measurements were rospectively defined as a afety parameter		

All VIVA-MIND results are preliminary and may be subject to change based on additional analysis and quality checks, however, the overall interpretation of the results is not expected to change significantly

© Vivoryon Therapeutics N.V.

¹ Due to the study being discontinued early, only 109 of 180 planned subjects were treated;² More information at clinicaltrials.gov ID NCT03919162; ³ Mild Cognitive Impairment (MCI) due to AD or Mild probable AD according to NIA-AA guidelines; BID: twice daily; MMSE: mini-mental state exam; CDR-SB: clinical dementia rating sum of boxes; eGFR: estimated glomerular filtration rate

VIVA-MIND Phase 2: Baseline characteristics and disposition

	VIVA-MIND total population ¹		
Demographics & baseline characteristics	Varoglutamstat N (%)	Placebo N (%)	
Number randomized	53	59	
Number of participants (mITT)	52	57	
Sex - n (%)			
Female	24 (46.2)	30 (52.6)	
Male	28 (53.8)	27 (47.4)	
Age (in years) - mean (SD)	72.9 (8.3)	70.8 (7.4)	
Average treatment duration (weeks) ² - mean (SD)	45.3 (24.1)	46.1 (26.0)	
CDR-SB at baseline ³ - mean (SD)	3.35 (1.53)	2.99 (1.70)	
eGFR (mL/min/1.73m2) at baseline ³ - mean (SD)	76.9 (16.3)	78.1 (17.8)	
Disposition ⁴	Varoglutamstat (%)	Placebo (%)	
Completed study (to week 72)	24.5%	33.9%	
Discontinued			
Termination by sponsor	37.7%	39.0%	
Withdrawal by subject	22.6%	18.6%	
All other	15.2%	8.5%	



¹ Total of 112 subjects randomized; 109 received study medication (mITT); ² Based on safety analysis population (N=53 varoglutamstat/N=56 placebo; one patient in placebo group received 7 single dose of varoglutamstat in error); ³ Baseline defined as last non-missing value prior to first study treatment administration; ⁴ Based on number randomized

VIVA-MIND analysis reveals no consistent effect of varoglutamstat 600mg BID on pre-specified AD endpoints

Pre-specified endpoints

- No clinically meaningful and no statistically significant differences between varoglutamstat 600mg BID and placebo for
 - CDR-SB
 - CFC2
 - ADAS-Cog 13
- Additional data including EEG, QPCT/L activity and other biomarkers in the CSF expected to become available in Q1 2025

Status and context

- VIVA-MIND was designed as a stage-gated seamless Phase 2a/b study with a total of 414 patients to be randomized
- The VIVA-MIND study was discontinued early based on the negative outcome of the VIVIAD study investigating a similar AD population and dose of varoglutamstat, where no clinically meaningful efficacy signal was observed
- Consequently, only 109 of the planned 180 patients were treated in the VIVA-MIND Phase 2a portion and the study did not progress into Phase 2b




CDR-SB: Clinical Dementia Rating Sum of Boxes; CFC2: Cognitive-Functional Composite 2; 8 ADAS-Cog-13: Alzheimer's Disease Assessment Scale cognitive subscale; EEG: electroencephalogram; CSF: Cerebrospinal fluid Varoglutamstat continues to demonstrate a favorable safety and tolerability profile with no new safety signals identified in VIVA-MIND

Adverse event category (%)	Varoglutamstat (N=53)*	Placebo (N=56)*	Overall (N=109)
any TEAE	84.9	78.6	81.7
any related TEAE	30.2	32.1	31.2
TEAE by severity			
mild	26.4	41.1	33.9
moderate	47.2	28.6	37.6
severe	11.3	8.9	10.1
serious TEAE	15.1	8.9	11.9
related serious TEAE	0	1.8	0.9
TEAE leading to any study drug dose modification (excluding discontinuation)	5.7	7.1	6.4
TEAE leading to study drug discontinuation	7.5	3.6	5.5
TEAE leading to death ¹	1.9	0	0.9

¹ One patient died after a head injury from a fall and the patient had a patient's provision to not resuscitate. A second patient had surgery for gastrointestinal bleeding after stopping study medication and died from complications of the surgery several weeks later. The deaths were considered not / unlikely related to varoglutamstat – the DSMB recommended continuation of study without changes after occurrence of these events during the study.



TEAE: Treatment emergent adverse events occurring during the treatment period; table does not include events occurring after end of treatment (EOT); * TEAEs are for Safety Analysis population which included patients who received ≥1 dose of varoglutamstat 600mg; the varoglutamstat arm includes one placebo patient who was identified as receiving a single dose of varoglutamstat in error and this person has been allocated to the varoglutamstat arm for Safety Analysis accordingly Statistically significant and clinically meaningful improvement vs. placebo in kidney function measured by eGFR (changes from baseline; total population; MDRD)




Placebo N=57, Varoglutamstat 600mg BID N=52

Calculations based on weighted average change from baseline

© Vivoryon Therapeutics N.V.

^a Corrected from the previously reported p<0.001 10

Sensitivity analysis: MDRD and CKD-EPI calculations show consistent and comparable statistically significant improvement vs. placebo on eGFR



Placebo N=57, Varoglutamstat 600mg BID N=52

Calculations based on weighted average change from baseline




^a Corrected from the previously reported p<0.001 11

Similarities and differences between VIVA-MIND and VIVIAD studies

Parameter	VIVA-MIND	VIVIAD
Study completion	Discontinued early (no AD efficacy signal in VIVIAD)	Completed
Patient selection	Mild AD, mean age 72	Mild AD, mean age 68
Number of patients treated	109	259
Varoglutamstat dose investigated	600mg BID	300 and 600mg BID
Dose escalation	Fast, starting at 150mg BID	Slow, starting at 50mg
Mean treatment duration	~46 weeks	~76 weeks
Number of patients with eGFR results week 36 and later	73	246

eGFR Results Comparison VIVA-MIND - VIVIAD




eGFR improvement of varoglutamstat versus placebo was consistent and statistically significant and clinically meaningful in both studies



Data includes all patients and all visits with data in the observation period; * Periods adjusted to slower dose escalation and longer treatment duration in VIVIAD. 13 MDRD calculation for eGFR, effect size calculated as weighted average; a Corrected from the previously reported p<0.001

Cross study comparison VIVA-MIND and VIVIAD eGFR Results – weeks 60 and 72 – Last two visits on treatment VIVA-MIND



Difference of eGFR change between varoglutamstat and placebo shows significant and clinically meaningful efficacy sustained until week 72 in VIVA-MIND consistent with results observed in VIVIAD

eGFR – estimated glomerular filtration rate based on creatinine and calculated using modification of diet in renal disease (MDRD) formula 14

© Vivoryon Therapeutics N.V.

Summary of kidney function data from varoglutamstat Phase 2 program

- ✓ Two double blind placebo-controlled studies one conducted in Europe and one in US showed consistent statistically significant and clinically meaningful improvement of eGFR for varoglutamstat versus placebo
- ✓ In both studies eGFR was improved above baseline and stabilized across the whole treatment period of 96 weeks (VIVIAD) and 72 weeks (VIVA-MIND)
- \checkmark The results provide robust evidence of a treatment benefit
- ✓ Good safety results in VIVA-MIND with the accelerated dose escalation scheme provide pathway for a convenient and commercially viable dosing schedule
- ✓ VIVA-MIND results fully support the sample size planning with 120 or fewer patients and previously communicated target effect size of 5mL/min/1.73m² for visits between week 24 and 72 for the planned Phase 2 study in DKD patients
- Analysis of VIVA-MIND data will continue



Financial Results & Outlook

Financials reflect prudent spending while refocusing on kidney disease

In €k	Nine months ended Sept. 30, 2024	Nine months ended Sept. 30, 2023
Revenue	0	0
Research & Development expenses	(12,582)	(10,449)
General & Administrative expenses	(4,897)	(6,803)
Net loss for the period	(17,143)	(17,120)
ln €k	Sept. 30, 2024	Dec. 31, 2023
Cash & cash equivalents	12,467	18,562*
Financial assets	59	10,165*

Updated cash runway into Q3 2025 – driven by cash utilization reduction through lower spending on clinical development and efforts to optimize operating expenses while supporting kidney disease strategy


Further funding and/or partnerships required to support potential future clinical studies and/or to extend cash runway beyond current guidance

© Vivoryon Therapeutics N.V.

* Liquid funds in amount of EUR 10m have been deposited on a short-term basis with banks as term deposits. 17 Thus, total liquid funds include cash & cash equivalents of EUR 18.6m and term deposits of EUR 10m.

Looking ahead: Upcoming value drivers

© Vivoryon Therapeutics N.V.



Vivoryon: Phase 2 program confirms varoglutamstat as a leading compound for further development in kidney disorders including DKD



Strong scientific base; novel MoA (QPCT/L inhibition); pE-CCL2 data confirms target engagement



Two independent studies; compelling long-term kidney function improvement; clear dose response



Extensive safety data package for varoglutamstat with convenient dose escalation scheme



Focused development plan for significant commercial opportunity in DKD and beyond



Additional potential orphan indications e.g. Alport Syndrome / Fabry Disease



Composition of matter patent protection¹ expected to 2044+



Cash runway into Q3 2025; actively pursuing funding and BD opportunities

¹ Current composition of matter patent to 2031 with additional potential for Hatch-Waxman extension of up to 5 years, new patent filings being evaluated. 10

© Vivoryon Therapeutics N.V.



Vivoryon Therapeutics N.V.

Halle (Saale) Weinbergweg 22 06120 Halle (Saale), Germany

Munich Franz-Josef-Delonge-Str. 5 81249 München, Germany

IR@vivoryon.com +49 (0)345 555 99 00

www.vivoryon.com